Approval · Notice of Compliance 2837 · 1998
DIDROCAL: Notice of Compliance 2837
Issued November 12, 1998
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2837
- Date
- November 12, 1998
- Company
- Procter & Gamble Pharmaceuticals Canada, IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indications: 1. prevention of bone loss in postmenopausal women who are at risk of developing osteoporosis; 2. prevention of corticosteroid induced osteoporosis
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIDROCAL | Not yet assigned | — |
Medicinal ingredients
- CALCIUM CARBONATE 500 MG per TAB
- ETIDRONATE DISODIUM 400 MG per TAB